NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Coherus Oncology, Inc. CHRS
14 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 42.2M
Revenue, FY2025 · full 14-year series below
Revenue $M
Net income $M
FY2025 · Revenue 42.2 · Net income 168.0
Compound annual growth
Revenue compounded at −38.4% a year over five years — but profit grew faster: net income at +4.9%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
398 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating -429.5% · Net 398.4%
ROE
FY2021 · ROE -151.6%
The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.3 | 0.2 | 0.3 | 0.5 | 0.4 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.2 | −0.2 | −0.2 | −0.3 | −0.3 | 0.2 | 0.1 | −0.2 | −0.2 | −0.1 | −0.2 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.2 | −0.2 | −0.2 | −0.3 | −0.3 | · | · | · | · | · | · | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
| Net income $B | 0.2 | 0.0 | −0.2 | −0.3 | −0.3 | 0.1 | 0.1 | −0.2 | −0.2 | −0.1 | −0.2 | −0.1 | −0.1 | −0.0 |
| Free cash flow $B | · | · | −0.2 | −0.2 | −0.0 | 0.1 | 0.0 | −0.2 | −0.2 | −0.3 | −0.1 | −0.0 | 0.0 | −0.0 |
| EPS, diluted $ | 1.43 | 0.25 | −2.53 | −3.76 | −3.81 | 1.62 | 1.23 | −3.22 | −4.48 | −3.04 | −6.01 | −10.64 | −16.10 | −15.85 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | −151.6 | 68.5 | 269.7 | · | −932.9 | −1778.4 | −736.9 | · | · | · |
| Shares out B | 0.12 | 0.12 | 0.11 | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 | 0.06 | 0.05 | 0.04 | 0.03 | 0.00 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 2 failures in 54 reconciliationsAUDITED
Reconciled in 12 of 19 fiscal years. 34 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente2 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2012